JP6725515B2 - 小分子を用いた鉄欠乏生物における生理機能の回復 - Google Patents

小分子を用いた鉄欠乏生物における生理機能の回復 Download PDF

Info

Publication number
JP6725515B2
JP6725515B2 JP2017534311A JP2017534311A JP6725515B2 JP 6725515 B2 JP6725515 B2 JP 6725515B2 JP 2017534311 A JP2017534311 A JP 2017534311A JP 2017534311 A JP2017534311 A JP 2017534311A JP 6725515 B2 JP6725515 B2 JP 6725515B2
Authority
JP
Japan
Prior art keywords
iron
hinokitiol
subject
small molecule
dmt1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017534311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504392A5 (https=
JP2018504392A (ja
Inventor
ディー バーク，マーティン
ディー バーク，マーティン
エス グリッロ，アンソニー
エス グリッロ，アンソニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2018504392A publication Critical patent/JP2018504392A/ja
Publication of JP2018504392A5 publication Critical patent/JP2018504392A5/ja
Application granted granted Critical
Publication of JP6725515B2 publication Critical patent/JP6725515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017534311A 2015-01-09 2016-01-11 小分子を用いた鉄欠乏生物における生理機能の回復 Active JP6725515B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562101706P 2015-01-09 2015-01-09
US62/101,706 2015-01-09
US201562251964P 2015-11-06 2015-11-06
US62/251,964 2015-11-06
PCT/US2016/012855 WO2016112381A1 (en) 2015-01-09 2016-01-11 Restoring physiology in iron-deficient organisms using small molecules

Publications (3)

Publication Number Publication Date
JP2018504392A JP2018504392A (ja) 2018-02-15
JP2018504392A5 JP2018504392A5 (https=) 2019-01-31
JP6725515B2 true JP6725515B2 (ja) 2020-07-22

Family

ID=56356533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534311A Active JP6725515B2 (ja) 2015-01-09 2016-01-11 小分子を用いた鉄欠乏生物における生理機能の回復

Country Status (5)

Country Link
US (2) US11517540B2 (https=)
EP (1) EP3242723B1 (https=)
JP (1) JP6725515B2 (https=)
AU (1) AU2016205030B2 (https=)
WO (1) WO2016112381A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700021676A1 (it) * 2017-02-28 2018-08-28 Carlo Angelo Ghisalberti Composizioni e sistemi di estrazione del ferro non-eme dalla dieta per uso nell’anemia sideropenica e carenze marziali
WO2019191270A1 (en) * 2018-03-27 2019-10-03 The Board Of Trustees Of The University Of Illinois Restoration of transmembrane copper transport
AU2019252933B2 (en) * 2018-04-13 2025-09-04 The Board Of Trustees Of The University Of Illinois Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
EP4045025A4 (en) * 2019-10-16 2023-11-22 Kinesid Therapeutics, Inc. TROPOLONE DERIVATIVES AND THEIR TAUTOMERS FOR IRON REGULATION IN ANIMALS
US20230406803A1 (en) * 2019-10-16 2023-12-21 Kinesid Therapeutics, Inc Tropolone derivatives and tautomers thereof for iron regulation in animals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176827A1 (en) 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
BR0315018A (pt) 2002-10-04 2005-09-06 Hoffmann La Roche Uso de anticorpos dos receptores de il-2 para prevenir toxicidade associada à terapia antimicótica com anfotericina b
EP1677759A1 (en) * 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
WO2006055412A1 (en) * 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
US20120135091A1 (en) * 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
EP2160473A4 (en) * 2007-05-14 2010-06-23 Toucan Capital Corp METHOD FOR IDENTIFYING COMPOUNDS THAT MODULATE THE REGULATION OF IRON RESPONSE ELEMENTS
GB0808835D0 (en) 2008-05-15 2008-06-18 Vitra Pharmaceuticals Ltd Therapeutic compositions
WO2010005851A1 (en) 2008-07-08 2010-01-14 Xenon Pharmaceuticals Inc. Combination therapy for treating iron disorders
MA33090B1 (fr) 2009-01-26 2012-03-01 Michael Spino Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer
US8372857B2 (en) 2009-06-30 2013-02-12 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
GB201101370D0 (en) 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
CN104105482B (zh) 2011-10-12 2017-10-24 思佰益药业股份有限公司 红细胞生成素产生促进剂
TW201400472A (zh) 2012-03-30 2014-01-01 Daiichi Sankyo Co Ltd ５－羥基嘧啶－４－甲醯胺衍生物
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof

Also Published As

Publication number Publication date
US20180263926A1 (en) 2018-09-20
EP3242723A1 (en) 2017-11-15
EP3242723A4 (en) 2018-07-25
EP3242723B1 (en) 2021-10-06
AU2016205030A1 (en) 2017-08-03
AU2016205030B2 (en) 2021-04-01
US11517540B2 (en) 2022-12-06
JP2018504392A (ja) 2018-02-15
WO2016112381A1 (en) 2016-07-14
US20230293452A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20230293452A1 (en) Restoring physiology in iron-deficient organisms using small molecules
JP6203995B2 (ja) 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
US20260091014A1 (en) Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
JP2007525472A (ja) 経口使用のための副甲状腺ホルモン（ｐｔｈ）含有医薬組成物
US12257238B2 (en) Magnesium biotinate compositions and methods of use
JPH0825875B2 (ja) ３―グアニジノプロピオン酸の代謝障害の治療用組成物
WO2022068910A1 (en) Use of antcin h and its derivatives for treating central nervous system diseases
KR20160110395A (ko) 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도
JP2024545685A (ja) Ｃｇｐの動物、真菌及び海洋供給源、並びに疾患管理のための、並びに非神経学的及び／又は神経学的状態の治療のための増大したｃｇｐ濃度
US12564600B2 (en) System for enhancing therapeutic compliance of the anti-cancer compound E7766
EA026713B1 (ru) Твердая пероральная лекарственная форма для лечения дефицита железа или анемии и ее применение
US20240077500A1 (en) Method for the detection and treatment of proteinopathies
US20210030725A1 (en) Restoration of transmembrane copper transport
AU2022389886A1 (en) Curcumin compositions and methods of use as an nk3 antagonist
WO2018192469A1 (en) Inhibitors of fabp4 and methods of treating arthritis
US20230142111A1 (en) Compositions and methods for the treatment of pervasive development disorders
WO2025240605A1 (en) Combination treatment
JP7048863B2 (ja) 非アルコール性脂肪肝疾患の治療法
JP2025519466A (ja) フロログルシノール製剤および使用方法
WO2026080585A1 (en) Treatment of retinal degeneration
WO2019161209A1 (en) Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses
CN119055650A (zh) 犬尿喹啉酸在治疗慢性肝硬化中的应用
US20060106026A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
JP2004163245A (ja) アトピー性皮膚炎治療薬評価法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200625

R150 Certificate of patent or registration of utility model

Ref document number: 6725515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250